Skip to Main Content
 Dunfa Peng, M.D., Ph.D.

Dunfa Peng, M.D., Ph.D.

Department:

DeWitt Daughtry Family Department of Surgery

Division:

Surgical Oncology

 Dunfa Peng, M.D., Ph.D.

Roles

  • Research Associate Professor
  • Biography

    Born in China and got my MD degree from Wannan Medical University in 1987, my MS degree of Pathology from Zhejiang University in 1992 and my Ph.D. degree from Shiga University of Medical Science Japan in 2003. I practiced two years as a surgeon and many years as a pathologist in China.

    I have been involved in the research on the tumors of gastrointestinal tract and digestive system for more than 20 years in China, Japan and USA. I have published more than 70 publications and presented in many national and international scientific meetings.

    My goal is to understand the molecular mechanisms underlying tumorigenesis and find the novel therapeutic strategies to treat them.
  • Education & Training

    Education

    • 2003
      Shiga University of Medical Science, Otsu, Japan
      PhD, Molecular Pathology
    • 1992
      Zhejiang University , Hangzhou, China
      MS, Pathology
    • 1987
      Wannan Medical College, Wuhu, China
      MD, Clinical Medicine

    Post Graduate Training

    • 2010
      Vanderbilt University , Nashville, TN
      Post-Doctoral Fellowship, Molecular pathways in Upper GI Cancers
    • 2006
      National Cancer Center Research Institute, Japan, Tokyo, Japan
      Post-Doctoral Fellowship, Epigenetics in pancreatic cancer
  • Honors & Awards

      Loading...

      No result found

    • Teaching Interests

      Teach and train postdoc fellow, medical students, new lab members about the molecular knowledge, experimental design, execution, technologies and skills, trouble shooting and manuscript writing, etc.
    • Research Interests

      I have strong interest in the research on the tumors of gastrointestinal tract and digestive system and have been working on this field for many years. My current research is to investigate the regulatory mechanisms and molecular functions of several molecular targets such as NRF2, NEK2 in esophageal adenocarcinoma (EAC), and to explore to target them using specific inhibitors as a novel therapeutic approach.

      The approaches used in our lab include 2D and 3D cultures (organotypic 3D culture, 3D organoids), and in vivo transgenic mice models, xenografting mice models and patients-derived xenografts. In addition to traditional molecular technologies, we apply cut-edge technologies, such as RNA-seq, CHIP-seq, single cell RNA-seq, Polysome-seq, Seahorse metabolism analyses and spatial transcriptomics and proteomics technologies.
    • Publications

      Loading...

      No result found

        Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
      • Professional Activities

          Loading...

          No result found